Published in Gastroenterology on March 08, 2008
Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39
Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol (2012) 4.22
Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet (2009) 3.99
Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst (2009) 2.57
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle (2012) 1.98
Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev (2009) 1.88
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology (2010) 1.71
Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch (2009) 1.67
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46
Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer (2010) 1.32
Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol (2014) 1.16
Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. Cancer Res (2010) 1.14
Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol (2014) 1.13
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. BMC Cancer (2010) 1.09
Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am J Pathol (2010) 1.07
Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf) (2015) 1.05
Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer Causes Control (2010) 1.04
Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology (2010) 1.01
Toward a comprehensive and systematic methylome signature in colorectal cancers. Epigenetics (2013) 1.00
Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology (2013) 0.98
A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J Cell Mol Med (2009) 0.96
Promoter methylation in the genesis of gastrointestinal cancer. Yonsei Med J (2009) 0.93
Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers. PLoS One (2012) 0.93
Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? BMC Cancer (2010) 0.91
BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer. Clin Epigenetics (2013) 0.89
Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics (2016) 0.84
Pathogenesis and management of serrated polyps: current status and future directions. Gut Liver (2014) 0.83
Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer. PLoS One (2015) 0.82
Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. PLoS One (2015) 0.81
Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma. Am J Pathol (2010) 0.81
Malignant melanoma arising from a perianal fistula and harbouring a BRAF gene mutation: a case report. BMC Cancer (2011) 0.78
[Molecular targets for colon cancer. VEGF, EGFR - and what else?]. Pathologe (2008) 0.78
Genome-wide linkage analysis and tumoral characterization reveal heterogeneity in familial colorectal cancer type X. J Gastroenterol (2014) 0.78
Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. Oncol Lett (2016) 0.75
RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis. Oncotarget (2016) 0.75
The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma – a report of a case. BMC Med Genet (2015) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res (1997) 9.94
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology (2005) 6.34
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut (2004) 4.06
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res (2001) 3.70
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A (2000) 3.65
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn (2007) 3.56
An elaborate pathway required for Ras-mediated epigenetic silencing. Nature (2007) 3.47
Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst (2006) 3.08
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Emerging concepts in colorectal neoplasia. Gastroenterology (2002) 2.44
Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer (2007) 2.36
Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol (2004) 2.27
Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell (2003) 2.24
Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res (2000) 1.95
CpG island methylation in colorectal adenomas. Am J Pathol (2001) 1.88
CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol (1999) 1.79
CIMP, at last. Gastroenterology (2005) 1.74
Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res (2007) 1.56
B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells. Cancer Res (2004) 1.46
HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers. Proc Natl Acad Sci U S A (2001) 1.41
Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene (2003) 1.38
Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res (2005) 1.38
CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene (2005) 1.31
The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology (2005) 1.30
P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology (2003) 1.27
Retracted Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. Int J Cancer (2006) 1.25
Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin Cancer Res (2003) 1.22
Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene (2004) 1.18
APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer. Int J Cancer (2006) 1.13
Differential involvement of the hypermethylator phenotype in hereditary and sporadic colorectal cancers with high-frequency microsatellite instability. Genes Chromosomes Cancer (2002) 1.04
High frequency of low-level microsatellite instability in early colorectal cancer. Cancer Res (2001) 0.91
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology (2004) 4.03
Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst (2013) 4.03
The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem (2003) 3.83
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med (2007) 3.41
Molecular classification and correlates in colorectal cancer. J Mol Diagn (2007) 3.25
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol (2013) 2.58
Lynch syndrome: form, function, proteins, and basketball. Gastroenterology (2005) 2.57
Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst (2009) 2.57
In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci U S A (2009) 2.46
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut (2012) 2.40
Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol (2013) 2.38
In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med (2006) 2.27
Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol (2004) 2.27
Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res (2003) 2.24
Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. Nat Biotechnol (2006) 2.21
A human beta-cell line for transplantation therapy to control type 1 diabetes. Nat Biotechnol (2005) 2.12
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 2.10
Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res (2011) 2.08
Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer (2003) 2.07
A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med (2004) 2.01
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology (2008) 1.97
Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res (2010) 1.88
Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology (2007) 1.82
Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res (2008) 1.81
Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol (2009) 1.80
The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer (2007) 1.76
Tumor-selective, adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection. Cell Cycle (2011) 1.76
Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev (2010) 1.74
Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J Clin Oncol (2007) 1.73
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology (2010) 1.71
Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol (2002) 1.71
APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther (2004) 1.71
Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol (2006) 1.70
Preliminary study of enteroscopy-guided, self-expandable metal stent placement for malignant small bowel obstruction. J Gastroenterol Hepatol (2012) 1.66
Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65
Intramuscular transplantation of engineered hepatic tissue constructs corrects acute and chronic liver failure in mice. J Hepatol (2009) 1.64
Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol (2010) 1.63
Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther (2009) 1.61
An assessment of the feasibility of sentinel lymph node-guided surgery for gastric cancer. Gastric Cancer (2004) 1.61
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59
No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients. Eur J Hum Genet (2008) 1.58
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther (2004) 1.57
Mucin function in inflammatory bowel disease: an update. J Clin Gastroenterol (2013) 1.55
Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol (2009) 1.54
Prevalence of the mismatch-repair-deficient phenotype in colonic adenomas arising in HNPCC patients: results of a 5-year follow-up study. Int J Colorectal Dis (2006) 1.54
Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother (2013) 1.53
Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells. Clin Cancer Res (2005) 1.50
Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg (2014) 1.46
Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46
Colorectal flat neoplasia. Dig Liver Dis (2003) 1.43
Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer (2005) 1.42
Heat shock protein A4 controls cell migration and gastric ulcer healing. Dig Dis Sci (2015) 1.42
Predictors of specialized intestinal metaplasia in patients with an incidental irregular Z line. Eur J Gastroenterol Hepatol (2010) 1.41
Metabolic syndrome is an independent risk factor for synchronous colorectal neoplasm in patients with gastric neoplasm. J Gastroenterol Hepatol (2012) 1.41
A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res (2003) 1.41
Participation and conflict in the decision-making process for endoscopic resection or surgical gastrectomy for early gastric cancer. J Surg Oncol (2012) 1.40
The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers. Genes Chromosomes Cancer (2007) 1.40
Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer (2011) 1.40
Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res (2011) 1.40
Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer (2011) 1.39
Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics (2011) 1.39
Incidence and predictive factors of irritable bowel syndrome after acute diverticulitis in Korea. Int J Colorectal Dis (2014) 1.39